EP1322663A1 - Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5- g(a)-androst-1-en-3-one and a process for preparing it - Google Patents

Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5- g(a)-androst-1-en-3-one and a process for preparing it

Info

Publication number
EP1322663A1
EP1322663A1 EP01948467A EP01948467A EP1322663A1 EP 1322663 A1 EP1322663 A1 EP 1322663A1 EP 01948467 A EP01948467 A EP 01948467A EP 01948467 A EP01948467 A EP 01948467A EP 1322663 A1 EP1322663 A1 EP 1322663A1
Authority
EP
European Patent Office
Prior art keywords
aza
ter
androst
butyl carbamoyl
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01948467A
Other languages
German (de)
French (fr)
Inventor
M. Satyanarayana Reddy
S. T. Rajan
M. V. N. Brahmeshwara Rao
K. Vyas
S. Vishnuvardhana Reddy
K. Shashi Rekha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Priority to EP06019093A priority Critical patent/EP1790653A3/en
Publication of EP1322663A1 publication Critical patent/EP1322663A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Definitions

  • the present invention relates to a novel polymorphic form of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one (Finasteride) of the formula (I)
  • the present invention also relates to process for preparing the novel polymorphic form of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- ⁇ -androst-l-en-3-one of the formula (I).
  • the polymorphic form of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- ⁇ - androst-l-en-3-one (5-alpha reductase inhibitor) is useful in treating acne, female hirsutism and particularly benign prostatic hyperplasia.
  • Polymorphism can be defined as the ability of the same chemical substance to exist in different crystalline structures.
  • the different structures are are referred to as polymorphs, polymorphic modification or form.
  • the polymorphic form-I is characterized by a differential scanning calorimetry (DSC) curve, at heating rate of 20°C/min and in a closed cup, exhibiting a minor endotherm with a peak temperature of about 232°C; an extrapolated onset temperature of about 223°C with an associated heat of about 11 joules / gm and by a major melting endotherm with a peak temperature of about of 261°C; an extrapolated onset temperature of about 258°C with an associated heat of about 89 J / gm.
  • the X-ray powder diffraction pattern is characterized by d-spacings of 6.44, 5.69, 5.36, 4.89, 4.55,
  • the polymorphic form-II is characterized by a differential scanning calorimetry (DSC) curve, at heating rate of 20°C / min and in a closed cup, exhibiting a single melting endotherm with a peak temperature of about 261°C; an extrapolated onset temperature of about 258°C, with an associated heat of about 89 J/g.
  • the X-ray powder diffraction pattern is characterized by d-spacings of 14.09, 10.36, 7.92, 7.18, 6.40, 5.93, 5.66, 5.31, 4.68, 3.90, 3.60 and 3.25.
  • the FT-IR spectrum (in KBr) shows bands at 3441, 3215, 1678, 1654, 1597, 1476 and 752 cm-1.
  • the two polymorphic forms referred as 1 and 2 are same as the Form-I and Form- II mentioned above.
  • the lattice contains one molecule of acetic acid. It decomposes losing acetic acid and recrystallizes in the range 170-174°C having melting point 255-257°C.
  • the lattice contains one molecule of ethyl acetate for two molecules of Finasteride.
  • the melting point of form lb is reported as 252-255°C. While doing process development to optimize the yield and quality of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- ⁇ -androst-l-en-3-one, different crystallization and isolation methods were used with different combinations of organic solvents and by varying the various parameters like temperature and volume etc.
  • Form-V which are different from Form-I and Form-II disclosed in the prior art.
  • Fig-1 Differential scanning calorimetry of Form-Ill.
  • Fig-2 X-Ray powder diffractogram of Form-Ill.
  • the present invention provides a novel polymorphic form
  • DSC exhibits a melting endotherm with a peak temperature of about 262°C and preceded by another minor endotherm at about 245°C and an exotherm at about 253°C.
  • the present invention provides a novel polymorphic form
  • DSC exhibits a melting endotherm with a peak temperature of about
  • Form -IN of 17- ⁇ -( ⁇ -ter. butyl carbamoyl)-4-aza-5- ⁇ -androst-l-en-3-one can be prepared by a process, which comprises: (i) preparing a slurry of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- - androst-l-en-3-one in ethyl acetate, tetrahydrofuran and water mixture such that the ratio of ethyl acetate:tetrahydrofuran : water is 1:1: ⁇ 0.1 and the ratio of this solvent mixture used is 1-3 volume/weight of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3- one;
  • Form-N of 17- ⁇ -( ⁇ -ter. butyl carbamoyl)-4-aza-5- ⁇ -androst-l-en-3-one of formula (I), can be prepared by a process which comprises:
  • the water immiscible organic solvent used in the process of preparing Form-Ill of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza-5- ⁇ -androst-l-en-3-one include any solvents such as halogenated solvent selected from dichloromethane or chloroform or aromatic hydrocarbon solvent preferably toluene or organic solvents selected from alkyl acetates preferably ethyl acetate.
  • the amount of aromatic hydrocarbon solvent is 25-50 volume/weight of 17- ⁇ -(N- ter. butyl carbamoyl)-4-aza-5- ⁇ -androst-l-en-3-one.
  • the alkyl acetate solvent is 10-20 volume/weight of 17- ⁇ -(N-ter. butyl carbamoyl)-4-aza- 5- ⁇ -androst-l-en-3-one.
  • the solvent selected are those in which 17- ⁇ -(N-ter. butyl carbamoyl)-4- aza-5- ⁇ -androst-l-en-3-one can be dissolved at room temperature (25-35° C) as in the case of halogenated solvents or else at elevated temperatures preferably at 40-50°C, as in case of aromatic hydrocarbon solvent or organic solvents selected from alkyl acetates, until dissolution is achieved.
  • polar organic solvents as used herein are meant to include solvents selected from C5-C10 aliphatic hydrocarbons either straight chain or branched, preferably hexane or heptane or petroleum ether, which precipitate 17- ⁇ -(N-ter. butyl carbamoyl)-4- aza-5- ⁇ -androst-l-en-3-one from the solution.
  • the step of saturating with a less polar organic solvent is carried out at a temperature in the range of 25-60 °C.
  • Trifluoroacetamide (2.5 gm) in toluene (25 ml) medium at 80-110°C. After completion of reaction, toluene layer was washed with 5-10% aqueous sodium sulphite solution (80 ml), and then with water (200ml). The toluene is stripped under vacuum to yield residual solid that is crude Finasteride.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel polymorphic form of 17-β-(N-ter.butyl carbamoyl)-4-aza-5--α-androst-1-en-3-one (Finasteride) of the formula (I) and processes for preparing the form.

Description

NONEL POLYMORPHIC FORM OF 17 - β- (Ν - TER. BUTYL CARBAMOYL) - 4 -
AZA - 5 - - AΝDROST - 1 - EΝ -3 - ONE AND A PROCESS FOR PREPARING IT
Field of Invention
The present invention relates to a novel polymorphic form of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one (Finasteride) of the formula (I)
CH3
The present invention also relates to process for preparing the novel polymorphic form of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of the formula (I).
The polymorphic form of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α- androst-l-en-3-one (5-alpha reductase inhibitor) is useful in treating acne, female hirsutism and particularly benign prostatic hyperplasia.
Background of Invention
Polymorphism can be defined as the ability of the same chemical substance to exist in different crystalline structures. The different structures are are referred to as polymorphs, polymorphic modification or form.
It has been known that 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l- en-3-one exists in two polymorphic forms i.e., Form-I and Form-II which are patented by Merck & Co. Inc. (US Patents are 5, 652, 365 and 5, 886, 184)
The polymorphic form-I is characterized by a differential scanning calorimetry (DSC) curve, at heating rate of 20°C/min and in a closed cup, exhibiting a minor endotherm with a peak temperature of about 232°C; an extrapolated onset temperature of about 223°C with an associated heat of about 11 joules / gm and by a major melting endotherm with a peak temperature of about of 261°C; an extrapolated onset temperature of about 258°C with an associated heat of about 89 J / gm. The X-ray powder diffraction pattern is characterized by d-spacings of 6.44, 5.69, 5.36, 4.89, 4.55,
4.31, 3.85, 3.59 and 3.14. The FT-IR spectrum (in KBr) shows bands at 3431, 3237,
1692, 1666, 1602 and 688 cm-1.
The polymorphic form-II is characterized by a differential scanning calorimetry (DSC) curve, at heating rate of 20°C / min and in a closed cup, exhibiting a single melting endotherm with a peak temperature of about 261°C; an extrapolated onset temperature of about 258°C, with an associated heat of about 89 J/g. The X-ray powder diffraction pattern is characterized by d-spacings of 14.09, 10.36, 7.92, 7.18, 6.40, 5.93, 5.66, 5.31, 4.68, 3.90, 3.60 and 3.25. The FT-IR spectrum (in KBr) shows bands at 3441, 3215, 1678, 1654, 1597, 1476 and 752 cm-1.
Two polymorphic forms and two pseudopolymorphic forms have been characterized using single crystal X-ray diffraction studies by Irena Wawrzycka et al and the results are published in the Journal of Molecular Structure, 474 (1999) 157-166.
The two polymorphic forms referred as 1 and 2 are same as the Form-I and Form- II mentioned above.
The pseudopolymorphic form la crystallizes in Monoclinic space group P2ι with cell dimensions a= 12.120(1) , b= 8.1652(7) , c= 13.577(1)A°, β = 111.530 ° containing two molecules in unit cell. The lattice contains one molecule of acetic acid. It decomposes losing acetic acid and recrystallizes in the range 170-174°C having melting point 255-257°C.
The pseudopolymorphic form lb crystallizes in orthorhombic space group P2ι2ι2ι having cell dimensions a = 8.173 (3), b= 18.364 (6) , c=35.65 (2) containing four molecules in unit cell . The lattice contains one molecule of ethyl acetate for two molecules of Finasteride. The melting point of form lb is reported as 252-255°C. While doing process development to optimize the yield and quality of 17- β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one, different crystallization and isolation methods were used with different combinations of organic solvents and by varying the various parameters like temperature and volume etc.
All samples which were isolated in different methods were submitted for regular analysis and subjected to polymorphic characterizations studies. From this we found that 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one exists in additional polymorphic / pseudopolymorphic forms namely Form-Ill, Form-IN, and
Form-V which are different from Form-I and Form-II disclosed in the prior art.
The XRD data and thermal characteristics of the pseudopolymorphic forms Form-IN and Form-N reasonably match with those of the pseudopolymorphs lb and la mentioned above respectively.
Brief Description Of Figures
Fig-1 : Differential scanning calorimetry of Form-Ill.
Fig-2: X-Ray powder diffractogram of Form-Ill.
Fig-3 : Infrared Spectra of Form-Ill. Summary of invention
Accordingly, the present invention provides a novel polymorphic form,
Form-Ill of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one which is characterized by the following data:
DSC: exhibits a melting endotherm with a peak temperature of about 262°C and preceded by another minor endotherm at about 245°C and an exotherm at about 253°C.(Fig-l)
XRD (2 θ) : 5.32, 10.70, 13.64, 14.96, 15.86, 16.12, 16.56, 17.20, 18.22,
19.60, and 23.04.(Fig-2)
FT-IR (InKBr) : 3427, 3233, 2931, 1679, 1600 , 1501, 1451 and 820' cm"1.(Fig-3)
According to another embodiment of the present invention, there is provided processes for preparing Form-Ill, Form-IN and Form-N of 17-β-(Ν-ter. butyl carbamoyl)-
4-aza-5-α-androst-l-en-3-one of formula (I).
Detailed Description of the Invention The present invention provides a novel polymorphic form,
Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one which is characterized by the following data:
DSC: exhibits a melting endotherm with a peak temperature of about
262°C and preceded by another minor endotherm at about 245°C and an exotherm at about 253°C.(Fig-l)
XRD (2 θ) : 5.32, 10.70, 13.64, 14.96, 15.86, 16.12, 16.56, 17.20, 18.22,
19.60, and 23.04.(Fig-2) FT-IR (hi KBr) : 3427, 3233, 2931, 1679, 1600 , 1501, 1451 and 820 cm"1.(Fig-3)
According to another embodiment of the present invention, there is provided a process for preparing Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α- androst-l-en-3-one of formula (I), which comprises:
(i) dissolving the crude 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α- androst-l-en-3-one in water immiscible organic solvents, such as halogenated solvent or aromatic hydrocarbon solvent or organic solvents selected from alkyl acetates; .
(ii) saturating the solution with less polar organic solvent, selected from aliphatic hydrocarbon either straight chain or branched, preferably hexane or heptane; or petroleum ether; and.
(iii) concentrating the solution and isolating the Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of formula (I) by conventional methods.
According to another embodiment of the present invention, there is provided an alternate process for preparing the Form-Ill of 17- β -(N-ter. butyl carbamoyl)-
4-aza-5-α-androst-l-en-3-one of formula (I), which comprises,
(i) dissolving any of the Form-I, Form-II, Form-IV and Form-N of 17-β-
(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of formula (I) in water immiscible organic solvents such as halogenated solvent or aromatic hydrocarbon solvent or organic solvents selected from alkyl acetates;
(ii) distilling off 60-70% of the solvent;
(iii) saturating the remaining solution with less polar organic solvents selected from aliphatic hydrocarbon either straight chain or branched, preferably hexane or heptane, or petroleum ether; and (iv) concentrating the resultant solution and isolating the Form-Ill of 17- β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of formula (I) by conventional methods.
Process used for the preparation of Form-IN and Form -V of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one of formula (I), are herein incorporated as reference .
Form -IN of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one can be prepared by a process, which comprises: (i) preparing a slurry of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- - androst-l-en-3-one in ethyl acetate, tetrahydrofuran and water mixture such that the ratio of ethyl acetate:tetrahydrofuran : water is 1:1: ~ 0.1 and the ratio of this solvent mixture used is 1-3 volume/weight of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3- one;
(ii) heating the resultant slurry to a temperature of 50 to 60°C,
(iii) cooling the slurry to -5 to 5°C; and
(iv) recovering the resultant solid by filtration and washing with chilled mixture of ethyl acetate and tetrahydrofuran and with petroleum ether to yield Form-IN of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of formula (I).
Form-N of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of formula (I), can be prepared by a process which comprises:
(i) dissolving 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3- one of formula (I) in aqueous acetic acid, that is, acetic acid : water in a ratio of 4 : 6, such that the amount of aqueous acetic acid is 5-15 volume/weight of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst- 1 -en-3-one;
(ii) heating the resultant mixture to 70-80°C;
(iii) cooling to 10-20°C; and
(iv) filtering the resulting material and isolating the Form-N of 17-β-(Ν- ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one of formula (I) by conventional methods.
The water immiscible organic solvent used in the process of preparing Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one include any solvents such as halogenated solvent selected from dichloromethane or chloroform or aromatic hydrocarbon solvent preferably toluene or organic solvents selected from alkyl acetates preferably ethyl acetate.
In the process for the preparation of Form-Ill polymorph, 17-β-(N- ter.butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one is dissolved in halogenated solvent such that the amount of halogenated solvent is 1-10 volume/weight of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one.
In case where the selected is aromatic hydrocarbon solvent preferably toluene, the amount of aromatic hydrocarbon solvent is 25-50 volume/weight of 17-β-(N- ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one.
In case where the selected solvent is alkyl acetates preferably ethyl acetate, the alkyl acetate solvent is 10-20 volume/weight of 17-β-(N-ter. butyl carbamoyl)-4-aza- 5-α-androst-l-en-3-one.
The solvent selected are those in which 17-β-(N-ter. butyl carbamoyl)-4- aza-5-α-androst-l-en-3-one can be dissolved at room temperature (25-35° C) as in the case of halogenated solvents or else at elevated temperatures preferably at 40-50°C, as in case of aromatic hydrocarbon solvent or organic solvents selected from alkyl acetates, until dissolution is achieved.
Less polar organic solvents as used herein are meant to include solvents selected from C5-C10 aliphatic hydrocarbons either straight chain or branched, preferably hexane or heptane or petroleum ether, which precipitate 17-β-(N-ter. butyl carbamoyl)-4- aza-5-α-androst-l-en-3-one from the solution. The step of saturating with a less polar organic solvent is carried out at a temperature in the range of 25-60 °C.
The present invention is described in the examples below, which can be provided by way of illustration only and does not limit the scope of the invention.
EXAMPLE 1
Preparation of Crude Finasteride 17β-(N-ter. Butyl carbamoyl)-4-aza-5α-androstane-3-one (1 gm) is reacted with 2,3 dichloro- 5,6 dicyano benzoquinone_(0.7 gm.and Bis-(trimethylsilyl)
Trifluoroacetamide (2.5 gm) in toluene (25 ml) medium at 80-110°C. After completion of reaction, toluene layer was washed with 5-10% aqueous sodium sulphite solution (80 ml), and then with water (200ml). The toluene is stripped under vacuum to yield residual solid that is crude Finasteride.
EXAMPLE 2
Conversion of Crude Finasteride to Form III
Crude Finasteride was dissolved in methylene chloride (3 ml) at 25-35°C.
This methylene chloride was saturated with petroleum ether (20 ml) at 25-30°C under stirring. The separated solid, after removal of methylene chloride and petroleum ether under reduced pressure at 50-60°C is isolated with petroleum ether (2 ml) at 10-15°C.
This solid was dried at ambient temperature, (yield: 0.8 gm ) EXAMPLE 3
Conversion of Finasteride Form I to Form III
Form-I of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one
(lgm) was dissolved in methylene chloride (3 ml ) and 60-70% of the methylene chloride was distilled off at 40-45°C. The resultant solution was saturated with petroleum ether
(10 ml) at 40-60°C under stirring. The solution was concentrated at 60-65°C at atmospheric pressure and then the resultant residual solid was kept under vacuum at 60-
65°C for about 30 minutes.
The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one (yield :
0.9 gm)
EXAMPLE 4
Conversion of Finasteride Form I to Form III
Form-I of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one (lgm) was dissolved in chloroform(3 ml) and 60-70% of the chloroform was distilled off at 60-70°C. The resultant solution was saturated with petroleum ether (10 ml) at 40-60°C under stirring. The solution was concentrated at 60-65°C at atmospheric pressure and the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield Form-Ill of 17-β- (N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one (yield : 0.9gm )
EXAMPLE 5
Conversion of Finasteride Form II to Form III
Form-II of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one
(lgm)was dissolved in methylene chloride (3 ml)and 60-70% of the methylene chloride was distilled off at 40-45°C. The resultant solution was saturated with pet. ether (10ml) at
40-60°C under stirring. The solution was concentrated at 60-65°C at atmospheric pressure and then the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield
Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one. (yield : 0.9 gm) EXAMPLE 6
Conversion of Finasteride Form II to Form III
Form-II of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one (1 gm) was dissolved in chloroform (3 ml) and 60-70% of the chloroform was distilled off at
60-70 °C. The resultant solution was saturated with petroleum ether(10 ml) at 40-60°C under stirring. The solution was concentrated at 60-65°C atmospheric pressure and then the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield Form-in of 17-β-
(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one. (yield : 0.9 gm)
EXAMPLE 7
Conversion of Finastride Form IV to Form III
Form IN of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one (1.0 gm) was dissolved in methylene chloride (3 ml)and 60-70% of the methylene chloride was distilled off at 40-45°C. The resultant solution was saturated with petroleum ether(10 ml) at 40-60°C under stirring. The solution was concentrated at 60-
65°C at atmospheric pressure and then the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3- one. (yield : 0.8 gm)
EXAMPLE 8
Conversion of Finastride Form IV to Form III
Form-IV of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- -androst-l-en-3-one (1 gm)was dissolved in chloroform(3 ml) and 60-70% of the chloroform was distilled off at 60-70°C. The resultant solution was saturated with petroleum ether(10 ml) at 40-60°C under stirring. The solution was concentrated at 60-65°C at atmospheric pressure and the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 hrs, to yield Form-in of 17- β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one. (yield : 0.8 gm)
EXAMPLE 9
Conversion of Finastride Form V to Form III
Form-V of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one
(1 gm) was dissolved in methylene chloride (3 ml) and 60-70% of the methylene chloride was distilled off at 40-45°C. The resultant solution was saturated with petroleum ether(10 ml) at 40-60°C under stirring. The solution was concentrated at 60-65°C at atmospheric pressure and the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield Form- Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one. (yield : Q.7gm)
EXAMPLE 10 Conversion of Finastride Form V to Form III Form-N of 17-β-(Ν-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one (1 gm) was dissolved in chloroform(3 ml) and 60-70% of the chloroform was distilled off at 60-70°C. The resultant solution was saturated with pet. ether (10 ml)at 40-60°C under stirring. The solution was concentrated at 60-65°C atmospheric pressure and then the resultant residual solid was kept under vacuum at 60-65°C for 30 min. The solid so obtained was isolated and dried in oven at 70-90°C for 8-12 h, to yield Form-IH of 17-β- (N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one. (yield : 0.7 gm)
EXAMPLE 11 Preparation of Finasteride Form IV Form-IV can be prepared by heating 17-β-(N-ter. butyl carbamoyl)-4-aza- 5-α-androst-l-en-3-one (lgm) in ethyl acetate, tetrahydrofuran and water mixture
(1.5ml+1.5 ml+0.1 ml) at 50-60°C for 25-30 min and cooling at -5° to 5°C for 30-45 min. The resulting solid was separated by filtration and washed with chilled mixture of ethyl acetate and tetrahydrofuran (0.5 ml+0.5 ml) and finally with petroleum ether (1 ml)and dried, (yield : 1.1 gm ) Any of Forms I, II, III or V can be used to prepared Form IN.
EXAMPLE 12 Preparation of Finasteride Form N Form-N can be prepared by heating 17-β-(Ν-ter. butyl carbamoyl)-4-aza- 5-α-androst-l-en-3-one (lgm) in aqueous acetic acid (7 ml ) (i.e., acetic acid : water 4: 6) at 70-80°C for about 25-30 min. After cooling the mixture at 10-20°C for 8-9 hours, the resultant solid was filtered and washed with water and suck dried, (yield : 0.8 gm) Any of Forms I, II, III or IN can be used to prepare Form V.

Claims

C L A I M S
A novel polymorphic Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5- α-androst-1- en-3-one having the formula (I),
which is characterized by the following data:
DSC: exhibits a melting endotherm with a peak temperature of about 262°C and preceded by another minor endotherm at about 245°C and an exotherm at about 253°C.(Fig-l)
XRD (2 θ): 5.32, 10.70, 13.64, 14.96, 15.86, 16.12, 16.56, 17.20, 18.22, 19.60, and 23.04. (Fig-2).
FT-IR (In KBr): 3427, 3233, 2931, 1679, 1600 , 1501, 1451 and 820 cm"1. (Fig-3).
2 A process for preparing Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-
5-α-androst-l-en-3-one, which comprises:
(i) dissolving crude 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst- l-en-3-one in a water immiscible organic solvents,
(ii) saturating the solution with less polar organic solvent,
(iii) concentrating the solution and isolating the Form III of 17-β-(N- ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one by conventional methods.
3. The process as claimed in step (i) of claim 2, wherein the water immiscible organic solvent is selected from halogenated solvent, aromatic hydrocarbon solvent, or organic solvents selected from alkyl acetates.
4. The process as claimed in claim 2, wherein the halogenated solvent is selected from dichloromethane or chloroform.
5. The process as claimed in claim 3, wherein the aromatic hydrocarbon solvent is toluene.
6. The process as claimed in claim 3, wherein the alkyl acetate is selected from ethyl acetate.
7. The process as claimed in step (ii) of claim 2, wherein the less polar organic solvents include solvents selected aliphatic hydrocarbon either straight chain or branched, preferably hexane or heptane or petroleum ether.
8. A process for preparing the Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4- aza-5- -androst-l-en-3-one, which comprises,
(i) dissolving any of the Form-I, Form-II, Form-IV and Form-V of 17- β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one in water immiscible organic solvents ,
(ii) distilling off 60-10% of the solvent,
(iii) saturating the remaining solution with less polar organic solvents, and
(iv) concentrating the resultant solution and isolating the Form-Ill of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one by conventional methods.
9. The process as claimed in step (i) of claim 8, wherein the water immiscible organic solvent is selected from halogenated solvent, aromatic hydrocarbon solvent, or organic solvents selected from alkyl acetates.
10. The process as claimed in claim 9, wherein the halogenated solvent is selected from dichloromethane or chloroform.
11. The process as claimed in claim 9, wherein the aromatic hydrocarbon solvent is selected from toluene.
12. The process as claimed in claim 9, wherein the alkyl acetate is selected from ethyl acetate.
13. The process as claimed in step (iii) of claim 8 wherein the less polar organic solvent include solvents selected aliphatic hydrocarbon either straight chain or branched, preferably hexane or heptane or petroleum ether.
14. Novel polymorphic Form III of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α- androst-l-en-3-one as described in the claim 1, substantially as herein described.
15. Process for preparing novel polymorphic Form III of 17-β-(N-ter. butyl carbamoyl)-4-aza-5-α-androst-l-en-3-one as claimed in claims 2-13, substantially as herein described in Examples 2-10.
EP01948467A 2000-09-07 2001-06-19 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5- g(a)-androst-1-en-3-one and a process for preparing it Ceased EP1322663A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06019093A EP1790653A3 (en) 2000-09-07 2001-06-19 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE073700 2000-09-07
IN737DE2000 2000-09-07
PCT/US2001/019546 WO2002020553A1 (en) 2000-09-07 2001-06-19 NOVEL POLYMORPHIC FORM OF 17-β-(N-TER.BUTYL CARBAMOYL)-4-AZA-5-α-ANDROST-1-EN-3-ONE AND A PROCESS FOR PREPARING IT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06019093A Division EP1790653A3 (en) 2000-09-07 2001-06-19 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it

Publications (1)

Publication Number Publication Date
EP1322663A1 true EP1322663A1 (en) 2003-07-02

Family

ID=11097081

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01948467A Ceased EP1322663A1 (en) 2000-09-07 2001-06-19 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5- g(a)-androst-1-en-3-one and a process for preparing it

Country Status (12)

Country Link
EP (1) EP1322663A1 (en)
JP (1) JP2004508380A (en)
AU (1) AU6991101A (en)
BR (1) BR0113732A (en)
CA (1) CA2422159A1 (en)
HU (1) HUP0300937A3 (en)
IL (1) IL154785A0 (en)
NO (1) NO20031045L (en)
NZ (1) NZ525116A (en)
PL (1) PL361014A1 (en)
WO (1) WO2002020553A1 (en)
ZA (1) ZA200302554B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2206065B1 (en) * 2002-10-31 2005-08-16 Ragactives, S.L. PROCEDURE FOR OBTAINING THE POLYMORPHIC FORM I OF FINASTERIDA.
EP1651661B1 (en) * 2003-07-03 2008-08-27 Cipla Ltd. Process for the preparation of finasteride form i
CN1294913C (en) * 2004-12-23 2007-01-17 鲁南制药集团股份有限公司 Medication combination of containing finasteride and cyclodextrin or ramification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225100A (en) * 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
US5091534A (en) * 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0220553A1 *

Also Published As

Publication number Publication date
HUP0300937A3 (en) 2007-10-29
CA2422159A1 (en) 2002-03-14
NO20031045D0 (en) 2003-03-06
NO20031045L (en) 2003-04-29
JP2004508380A (en) 2004-03-18
PL361014A1 (en) 2004-09-20
ZA200302554B (en) 2004-02-19
NZ525116A (en) 2004-11-26
WO2002020553A1 (en) 2002-03-14
HUP0300937A2 (en) 2007-02-28
BR0113732A (en) 2003-07-29
IL154785A0 (en) 2003-10-31
AU6991101A (en) 2002-03-22

Similar Documents

Publication Publication Date Title
CA2514169C (en) Process for obtaining 17.alpha.-acetoxy-11.beta.(4-n,n-dimethylaminophenyl-19-norpregna-4,9-diene-3,20-dione
RU2230748C2 (en) Method for preparing clarithromycin as crystals of form ii
EP1112280B1 (en) Method of preparing form ii crystals of clarithromycin
NO160261B (en) ANALOGY PROCEDURE FOR PREPARING THE THERAPEUTIC ACTIVE COMPOUND N-METHYL-11-AZA-10-DEOKSO-10-DIHYDROERYTROMYCIN A.
JP2005523927A (en) Improved synthesis of cyproterone acetate.
EP1322663A1 (en) Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5- g(a)-androst-1-en-3-one and a process for preparing it
KR101446825B1 (en) Process for preparing aromatase inhibitors
AU2001269911A1 (en) Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
AU2001269911B2 (en) Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
EP1790653A2 (en) Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
NO180450B (en) Pharmaceutical formulations and process for the preparation of Form II dirithromycin
EP2080764A1 (en) Solid forms of ortataxel
IL102539A (en) Preparation of 17beta-substituted-4- aza-5alpha-androstan-3-one derivatives
CN108239134B (en) Obeticholic acid intermediate and preparation method and application thereof
BOBILLOT et al. Chemical modification of tylosin
KR930001165B1 (en) Process for the preparation of 4'-deoxydoxorubicin
SU1641829A1 (en) Method of producing cholesterol ester of o-cumaric acid
CN115232092A (en) Preparation method of 10-acetyl docetaxel
US20060247452A1 (en) Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
CN111269257A (en) Preparation method and application of Marizonib key intermediate
BE531443A (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030401

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20041206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20061021